Daily BriefsEquity Bottom-Up

Equity Bottom-Up: Pinduoduo, Alibaba Group, China Power International, Premier Anti-Aging, ASICS Corp, Vanguard Intl Semiconductor, PHC Holdings, Xometry and more

In today’s briefing:

  • Pinduoduo (PDD): 4Q21, Undervalued Growth Rate and Record Profit Since IPO, Buy
  • US Expansion of Travel Bans the First Step in Broader Escalation?
  • China Power International (2380 HK): Transformation to Soon Bear Fruits
  • Premier Anti-Aging Company:  Getting to an Interesting Level
  • ASICS (7936): Time for a Bounce
  • Vanguard (5347.TT): We Think Vanguard Can Easily Reach 1Q22 Guidance.
  • PHC Holdings (6523 JP): Eyeing a Bigger Pie of Global Diabetes Management Solution
  • Recent IPO Insights: Xometry

Pinduoduo (PDD): 4Q21, Undervalued Growth Rate and Record Profit Since IPO, Buy

By Ming Lu

  • PDD’s total revenue growth was low 4Q21, as the company gave up on direct sales.
  • However, we believe the revenue growth will bounce back in 2023.
  • PDD cut sales and marketing expense, so we believe operating margin will improve in following two years.

US Expansion of Travel Bans the First Step in Broader Escalation?

By Mio Kato

  • The US just expanded travel bans against Chinese officials said to be repressing ethnic and religious minorities. 
  • The timing, a few days after a Biden-Xi call on Russia that appeared to achieve little of substance is telling. 
  • Noises out of the UK have been similarly aggressive here and the question now is how Europe responds.

China Power International (2380 HK): Transformation to Soon Bear Fruits

By Osbert Tang, CFA

  • 2H21 is bad for China Power International (2380 HK) as coal price surged. But the positive news is that its wind and solar segments logged a 50.6% full-year profit growth.
  • There is good progress on transformation and it has 7GW of clean energy capacity to come on stream in FY22. This is equivalent to 46% of the existing capacity.
  • CPI said coal-fired plants are marginally profitable in Jan-Feb; meanwhile, hydropower will do better in this year. Overall, these set the stage for a turnaround.

Premier Anti-Aging Company:  Getting to an Interesting Level

By Oshadhi Kumarasiri

  • We last wrote on this relatively small Japanese cosmetics company in September 2021 suggesting that it could be worth keeping an eye on given its cheaper valuation compared to peers.
  • Premier Anti-Aging (4934 JP) shares are down 80% from the peak, mostly because it was sold-off alongside the low quality names in Mothers.
  • It seems early to turn outright bullish on Premier Anti-Aging yet. However, if you are short other unprofitable names in Mothers, we think Premier Anti-Aging is a sensible long hedge.

ASICS (7936): Time for a Bounce

By Mark Chadwick

  • Demand for ASICS running shoes remains strong. That should become clear as factories reach full capacity and shipping problems recede.
  • Profit margins will expand due to less discounting and an improved channel mix. 
  • We turn bullish following a 30% decline from 52-week high. The stock is now trading at undemanding multiples versus peers.  

Vanguard (5347.TT): We Think Vanguard Can Easily Reach 1Q22 Guidance.

By Patrick Liao

  • It’s NTD$4.976~5.176bn to go in March to reach the 1Q22 guidance of NTD$13.2~13.6bn.
  • Despite Consumer and Smartphone demands could be weak in 1Q because of seasonality, we still see the demands can be strong in PMIC, Auto, 5G and etc.
  • For the continuous 8” demand, the clients have high willingness to sign up an LTA (long term agreement), which explains the strong demand situation now.  

PHC Holdings (6523 JP): Eyeing a Bigger Pie of Global Diabetes Management Solution

By Tina Banerjee

  • PHC Holdings (6523 JP) is a diversified healthcare company, which serves ~$25 billion broader end-market, of which global glucose monitoring is the largest end-market.
  • The company’s diabetes management business is the highest margin earning segment and is poised to grow through expanding presence in continuous glucose monitoring system.
  • PHC can be an early investment idea as a passive play on the fastest growing segment of the global diabetes management segment ahead of its global launch of next-generation CGM.

Recent IPO Insights: Xometry

By Aaron Gabin

  • Two-Sided online marketplace connecting buyers and sellers. But is this more Amazon or Angi?
  • Game changing acquisition in December of Thomas should turbocharge growth and margins for 2022-2023.
  • At 4x sales, this is a very high growth asset that has been crushed since IPO, down 55%. Interesting entry point.

Related tickers: Pinduoduo (PDD.O), Alibaba Group (BABA.N), China Power International (2380.HK), ASICS Corp (7936.T), Vanguard Intl Semiconductor (5347.TWO)

Before it’s here, it’s on Smartkarma